| Serial Number | 98377989 |
| Word Mark | AMP |
| Filing Date | Friday, January 26, 2024 |
| Status | 802 - REQUEST FOR EXTENSION OF TIME TO FILE OPPOSITION |
| Status Date | Thursday, April 17, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, March 18, 2025 |
| Goods and Services | Biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organism in the manufacturing process; custom manufacture for others of products relating to biotechnology, namely, recombinant proteins for use in the biotechnology industries; custom manufacture for others of cell therapy products; custom manufacture for others of gene therapy products; custom manufacture of pharmaceuticals in accordance with specific standards GMP regulations |
| Description of Mark | The mark consists of the word "AMP" in capital letters above a design suggestive of a chromosome with an electrical bolt forming the junction of the two halves of the chromosome. |
| Pseudo Mark | ADVANCED MEDICINE PARTNERS |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | Contract development and manufacturing organization (CDMO) services, namely, pharmaceutical drug development services; consulting and advisory services in the field of analytical development and quality control testing of pharmaceutical, gene therapy, and cell therapy products; consulting and advisory services in the field of manufacturing process development for pharmaceutical, gene therapy and cell therapy products; consulting in the field of chemistry manufacturing and controls (CMC) activities; testing of pharmaceutical, gene therapy, and cell therapy products and materials; quality control testing of pharmaceutical products and materials, namely, biopharmaceutical products and materials in accordance with specifications or requirements of regulatory standards applicable in target countries; testing and validation services of biopharmaceutical products to assure compliance with global regulatory requirements, specifications, and industry standards for pharmaceutical, cell therapy and gene therapy methods of development; technical consulting for regulatory compliance in the field of chemistry manufacturing and controls (CMC) |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, May 6, 2024 |
| Primary Code | 040 |
| First Use Anywhere Date | Tuesday, January 16, 2024 |
| First Use In Commerce Date | Tuesday, January 16, 2024 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, May 6, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | Tuesday, January 16, 2024 |
| First Use In Commerce Date | Tuesday, January 16, 2024 |
| Party Name | JAGUAR GENE THERAPY, LLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | LAKE FOREST, IL 60045 |
| Party Name | JAGUAR GENE THERAPY, LLC |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | LAKE FOREST, IL 60045 |
| Party Name | Advanced Medicine Partners, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Lake Forest, IL 60045 |
| Event Date | Event Description |
| Wednesday, February 5, 2025 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Thursday, April 17, 2025 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Tuesday, August 20, 2024 | NON-FINAL ACTION WRITTEN |
| Friday, February 21, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, January 30, 2024 | NEW APPLICATION ENTERED |
| Monday, May 6, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, March 18, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, March 18, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Thursday, February 20, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, February 19, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, August 20, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, March 12, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 7, 2024 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Wednesday, February 19, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, August 12, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, August 20, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, November 15, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Friday, November 15, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |